DAEJEON, South Korea, Oct. 30, 2026 /PRNewswire/ -- REMOSHOT Co., Ltd., a developer of extended reality (XR) software and content, announced that it is enhancing its DoDrill XR vocational training platform using patented technology from the Korea Institute of Science and Technology Information (KISTI).
The company said it is using KISTI's "XR Content Authoring Technology" to further develop DoDrill's multiuser collaboration and spatial authoring features, which were partially unveiled at World IT Show 2025.
Headquartered in Daedeok Innopolis in Daejeon, with a research laboratory in Yuseong, REMOSHOT operates in XR markets in South Korea and abroad. The company specializes in developing software and content using extended reality (XR) technologies, including virtual reality (VR), augmented reality (AR), and mixed reality (MR). It has collaborated with institutions in South Korea involved in specialized professional fields to provide professional and systematic vocational training services. DoDrill is a specialized training platform designed for the nursing and caregiving sectors, as well as the field of air navigation safety.
The main features of DoDrill, REMOSHOT's specialized vocational training platform, are as follows:
1. Cross-Device Support
DoDrill allows users to connect to and participate in a virtual 3D environment simultaneously using various digital devices, including VR head-mounted displays (HMDs), PCs, mobile devices, and tablets.
2. Multiuser Participation
Users can access training content across supported devices with or without logging in. Through real-time communication, participants can observe one another's actions and roles as they interact within the virtual environment, supporting collaborative training scenarios.
3. Scene Master Editor
The platform allows users to upload and modify training scenarios and 3D environments, customize content, and continuously enhance training content by incorporating new scenarios.
4. Language Support
DoDrill initially supports three languages, Korean, English, and Vietnamese, for key countries where the platform is expected to gain traction. As the market expands, REMOSHOT plans to add support for other languages, including Thai, Japanese, and Chinese.
For more information on REMOSHOT and DoDrill, please visit the official website:
https://www.remoshot.com/
https://dodrill.kr/
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
XR Technology Developer REMOSHOT Pursues New Market Opportunities with KISTI's Patented Technology
BOSTON, , Oct. 31, 2026 /PRNewswire/ -- Dr. Yang Liu, Director of Medicinal Chemistry at Revolution Medicines, Inc., and Dr. Kristof Pota, Senior Scientist, visited Medicilon's Nanhui R&D Center. Dr. Maosheng Duan, President of Medicilon's Drug Discovery and Pharmaceutical Research Divisions, Dr. Jian Wang, Vice President of Medicilon, and their team welcomed them. The two parties held in-depth discussions on project progress, data transfer, and strategic priorities for the coming year. During the visit, Medicilon presented Revolution Medicines with the "Excellence in Client Partnership Award," recognizing the substantial clinical value of the company's pioneering pan-KRAS drug discovery and development. The award also honors years of joint effort, mutual trust, and shared success by both R&D teams, setting an outstanding example of bilateral collaboration.
A Three-Year Partnership Built on a Trusted R&D Model
Over the past three years, Medicilon's FTE team has worked closely with Revolution Medicines to tackle R&D technical challenges, consistently prioritizing client needs and focusing on the single objective of efficiently delivering high-quality molecules. This partnership has established a model of mutual trust and robust CRO–client collaboration.
At the award ceremony, Dr. Duan commended Revolution Medicines for its pioneering work in advancing KRAS—a target once deemed "undruggable"—and congratulated the company on the U.S. FDA's August 2026 approval of the NDA for Daraxonrasib for metastatic pancreatic cancer. This milestone offers new hope for pancreatic cancer patients and delivers significant clinical value. The Excellence in Client Partnership Award recognizes the trust, dedication, and achievements of both teams over more than three years of collaboration, reflecting Medicilon's confidence in a deeper, long-term partnership.
In-Depth Discussions Explore New Collaboration Opportunities
During the discussions, Dr. Wang outlined Medicilon's growth and its integrated R&D platform spanning target discovery to IND submission. Medicilon's quality system meets international standards and holds NMPA, OECD GLP, FDA GLP, and AAALAC accreditation. Its advanced platforms support ADC/AOC, TPD, RIPTAC, RNAi, and peptide programs. Both parties discussed cross-regional data transfer, project management, future collaboration, and ways to enhance cross-border R&D efficiency.
Laboratory Tour
Subsequently, Drs. Liu and Pota toured Medicilon's R&D laboratories, visiting the chemistry and oligonucleotide labs as well as the API and preclinical research facilities, gaining firsthand insight into Medicilon's R&D infrastructure and quality management system.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Medicilon Presents Revolution Medicines with the "Excellence in Client Partnership Award"
